Guidance
← 실적 발표
01
02
03
04 05 06
톤
자본지출
A1 A2 A3 A4 A5
REGN
FY2026 Q1
개선
Regeneron Pharmaceuticals, Inc. 실적 발표
Buzzberg 분석
Dupixent growth and margin improvement expected to boost collaboration revenue
Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47.
Buzzberg 분석 Dupixent growth and margin improvement expected to boost collaboration revenue Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47. 전체 분석 보기분석 접기
Regeneron reported strong Q1 2026 with 19% revenue growth and 15% EPS growth, driven by Dupixent, ILEA-HD, and Libtio. Management struck a confident tone, highlighting pipeline progress across immunology, oncology, and metabolic diseases, and announced a new $3 billion buyback. They also discussed the MFN pricing agreement with the US government and a near-term revenue step-up from the Sanofi collaboration. Total revenues grew 19% YoY to $3.6B, EPS grew 15% to $9.47.
- Dupixent global sales grew 31% to $4.9B, with new indications approved.
- ILEA franchise is bifurcating: ILEA-HD +52% YoY, ILEA declining as biosimilars approach.
- Pipeline progress highlighted: positive Phase 3 for C5 siRNA in MG, Phase 3 data for GLP-1/GIP partner, and BLA acceptance for garitosumab.
매출$3.6054B-7% 전분기 대비
주당순이익(EPS)$9.47-17% 전분기 대비
매출총이익률81.43%보고값
영업이익률17.83%보고값
근거 있는 핵심 내용 6개
지금 중요한 점
이번 발표에서 가장 의미 있는 변화를 정리했습니다.
Pipeline
Fianelmab melanoma PFS data expected later this quarter
Regulatory
Eylea HD PFS decision expected this quarter after FDA miss
핵심 내용 3개 더 보기
Capital Allocation
New $3 billion buyback authorized, with $3.4 billion available
Pipeline
Obesity combo with Praluent positioned as preferred GLP-1
Data
Linazific infectious risk decreases with longer treatment
보고 기간
보고 실적
| 지표 | 보고값 | 변화 |
|---|---|---|
| 매출 | $3.6054B | -7% 전분기 대비 |
| 주당순이익(EPS) | $9.47 | -17% 전분기 대비 |
| 매출총이익률 | 81.43% | 보고값 |
| 영업이익률 | 17.83% | 보고값 |
| 잉여현금흐름 | $0.8483B | -8% 전분기 대비 |
| 자본지출 | $0.2306B | 보고값 |
향후 전망
향후 가이던스
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| 매출총이익률 | FY2026 | 77%–78% | 77.5% | 유지 |
AI, 자본지출 및 수요 분석
경영진 분석
Confident
Management struck a confident tone, highlighting strong commercial execution, pipeline progress, and a new share repurchase authorization, while framing challenges like the FDA delay on the pre-filled syringe as near-term issues.
투자 및 생산능력
Management noted a temporary interruption in bulk manufacturing at its Limerick, Ireland site, which has resumed initial production and is expected to return to full production by the end of the second quarter. GAAP gross margin guidance was lowered to 77%-78% due to related costs, but product availability was not impacted.
아래에 언급된 기업 1개 모두 표시
기업발표 이후 수익률
파트너
파트너
Dr. Leonard Schleifer
Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue. — This is a significant, durable revenue tailwind for Regeneron from Q3 onwards.
근거
“Maybe it'll give me an opportunity to publicly thank Paul Hudson for all the work he did on Dupixent since 2019...”
외부 신호
공급망 알파 · 5발표 이후 수익률
Sanofi collaboration revenue will step up starting Q3 2026 as the development balance is fully repaid, materially boosting Regeneron's recognized revenue.
근거
“We now expect the Sanofi development balance to be fully repaid by the end of the second quarter. As a result, we expect Sanofi collaboration revenue to step up to reflect our full share of collaboration profits starting in the third quart…”
ILEA (Eylea) demand is expected to decline in the mid-to-high teens QoQ in Q2 ahead of new biosimilar launches, while ILEA-HD demand grows ~10% sequentially.
근거
“...for ILEA, we anticipate that demand will decline in the mid to high teens in the second quarter ahead of the potential launch of additional biosimilars in the second half of the year coupled with the factors that I highlighted earlier.”
Regeneron has a strategic goal to match up to $200 million in 2026 for patient assistance contributions via Good Days, with Q1 contributions de minimis.
근거
“We remain committed to matching up to $200 million in 2026 to support patient access and affordability.”
GAAP gross margin will be negatively impacted in Q2 due to a temporary interruption in bulk manufacturing at Limerick, Ireland, with production resuming to full capacity by end of Q2.
근거
“We have now resumed initial production in the facility and expect to resume full production by the end of the second quarter. As a result, we anticipate our GAAP gross margin will continue to be negatively impacted in the second quarter as…”
Regeneron is developing next-gen IL-13 antibodies and is planning an expedited path to approval, seeking to broaden the atopic dermatitis market to include mild patients.
근거
“We don't necessarily think about having to exactly replace or work on. We have nearly 50 things in the pipeline, and we're looking forward to bringing as many important ones forward as we can.”
방법론 및 범위
경영진 발언만 분석합니다. 검증된 기업 언급 1개를 모두 표시하며, 보고 실적과 향후 가이던스를 분리합니다. 공개 근거는 화자가 표시된 짧은 인용문 8개로 제한됩니다. AI 분석은 불완전하거나 틀릴 수 있으므로 중요한 주장은 원문에서 확인하세요.